268 related articles for article (PubMed ID: 3858272)
1. Clinical value of CA 19-9 (carbohydrate antigen) in gastrointestinal adenocarcinoma.
Mennini G; Silecchia G; Zanna C; Cucchiara G; Spadaro G; Greco E; Basoli A; Speranza V
Ital J Surg Sci; 1985; 15(1):37-43. PubMed ID: 3858272
[TBL] [Abstract][Full Text] [Related]
2. The clinical validity of circulating tumor-associated antigens CEA and CA 19-9 in primary diagnosis and follow-up of patients with gastrointestinal malignancies.
Staab HJ; Brümmendorf T; Hornung A; Anderer FA; Kieninger G
Klin Wochenschr; 1985 Feb; 63(3):106-15. PubMed ID: 3856076
[TBL] [Abstract][Full Text] [Related]
3. [Ca 12-5 in stomach and colorectal cancer. A comparison with the tumor markers CEA and Ca 19-9].
Quentmeier A; Schlag P; Geisen HP; Schmidt-Gayk H
Med Klin (Munich); 1986 Mar; 81(6):199-201. PubMed ID: 3466003
[No Abstract] [Full Text] [Related]
4. Clinical aspects of the CEA test.
Laurence JR; Neville AM
Bull Cancer; 1976; 63(4):473-81. PubMed ID: 1021177
[No Abstract] [Full Text] [Related]
5. [Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen in gastrointestinal neoplasms. Comparison of markers].
Capocasale E; Contini S; Rossetti A; Del Sante G; Gregori G
Acta Biomed Ateneo Parmense; 1985; 56(6):231-6. PubMed ID: 2940782
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of monoclonal antibodies to carcinoembryonic antigen, tissue polypeptide antigen, alpha-fetoprotein, carbohydrate antigen 50, and carbohydrate antigen 19-9 in the diagnosis of colorectal adenocarcinoma.
Alvarez JA; Marín J; Jover JM; Fernández R; Fradejas J; Moreno M
Dis Colon Rectum; 1995 May; 38(5):535-42. PubMed ID: 7537651
[TBL] [Abstract][Full Text] [Related]
7. [CA 12-5 in cancer of the digestive tract. A comparison with CA 19-9 and CEA in cancer of the pancreas and colon].
Klapdor R; Klapdor U; Bahlo M; Dallek M; Kremer B; van Ackeren H; Schreiber HW; Greten H
Dtsch Med Wochenschr; 1984 Dec; 109(51-52):1949-54. PubMed ID: 6595110
[TBL] [Abstract][Full Text] [Related]
8. [CA-19-9, CA50 and CEA in pancreatic and gastrointestinal tumors. Comparative studies].
Dienst C; Clodius T; Oldörp T; Uhlenbruck G; Diehl V
Med Klin (Munich); 1987 Jan; 82(2):45-50. PubMed ID: 3470595
[No Abstract] [Full Text] [Related]
9. Carbohydrate antigenic determinant (CA 19-9) and other tumor markers in gastrointestinal malignancies.
Yoshikawa T; Nishida K; Tanigawa M; Fukumoto K; Kondo M
Digestion; 1985; 31(2-3):67-76. PubMed ID: 2581838
[TBL] [Abstract][Full Text] [Related]
10. [Clinical evaluation of the tumor marker CA 19-9 in comparison with carcinoembryonic antigen (CEA) in surgical pre- and postoperative diagnosis].
Lorenz M; Happ J; Hottenrott C; Maul FD; Baum RP; Hör G; Encke A
Nuklearmedizin; 1986 Feb; 25(1):9-14. PubMed ID: 3459133
[TBL] [Abstract][Full Text] [Related]
11. The combined use of CA 19-9 and carcino-embryonic antigen (CEA) in malignancies of the gastrointestinal tract.
Staab HJ
Acta Gastroenterol Belg; 1987; 50(1):29-35. PubMed ID: 3480668
[No Abstract] [Full Text] [Related]
12. [The tumor-associated antigen CA 19-9 in the differential diagnosis and course control of malignancies of the pancreas and the gastrointestinal tract].
Klapdor R; Greten H
Dtsch Med Wochenschr; 1984 Dec; 109(50):1935-9. PubMed ID: 6210188
[No Abstract] [Full Text] [Related]
13. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
Nishida K; Tasaki N; Miyagawa H; Yoshikawa T; Kondo M
Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536
[TBL] [Abstract][Full Text] [Related]
14. A clinical evaluation of carbohydrate antigen 19-9 and carcinoembryonic antigen in patients with pancreatic carcinoma.
Satake K; Kanazawa G; Kho I; Chung YS; Umeyama K
J Surg Oncol; 1985 May; 29(1):15-21. PubMed ID: 3857396
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous radioimmunoassay for carcinoembryonic antigen (CEA) and alpha-fetoprotein (alphaFP) in neoplasms of the gastro-intestinal tract.
McIntire KR; Waldmann TA; Go VL; Moertel CG; Ravry M
Ann Clin Lab Sci; 1974; 4(2):104-8. PubMed ID: 4819750
[No Abstract] [Full Text] [Related]
16. [Assay of serum carbohydrate antigen (CA) 19-9 in the diagnosis of gastric cancer].
Nishida K; Yamamoto T; Yoshioka K; Iida M; Miyagawa H; Yoshikawa T; Sugino S; Kondo M
Gan To Kagaku Ryoho; 1986 Jan; 13(1):101-8. PubMed ID: 3455804
[TBL] [Abstract][Full Text] [Related]
17. [Clinical evaluation of CA 19-9 for the detection of malignant tumors--a comparison with CEA and IAP].
Furukawa M; Kazaka S; Kushibiki K; Ashida Y; Saito H; Yamamoto H; Furukawa T
Gan No Rinsho; 1984 Apr; 30(4):357-62. PubMed ID: 6587133
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Ca 12-5 as a tumor marker for gastric and colo-rectal cancer in comparison to CEA and Ca 19-9.
Quentmeier A; Schlag P; Geisen HP; Schmidt-Gayk H
Eur J Surg Oncol; 1987 Jun; 13(3):197-201. PubMed ID: 3474158
[TBL] [Abstract][Full Text] [Related]
19. [New monoclonal antibodies in the diagnosis of gastrointestinal cancers].
Heptner G; Domschke S; Domschke W
Internist (Berl); 1986 Nov; 27(11):723-8. PubMed ID: 2433247
[No Abstract] [Full Text] [Related]
20. [Clinical value of the plasma-CEA-concentrations in the primary diagnosis of malignoma of the digestive tract].
Aver IO; Münch L; Epping J; Schmid L
Z Gastroenterol Verh; 1976; (11):73-7. PubMed ID: 65868
[No Abstract] [Full Text] [Related]
[Next] [New Search]
